Abstract Embargo Policy
All meeting attendees, members of the media, companies, institutions, organizations, universities, investment advisors, and all other individuals are required to abide by the embargo policy governing the American Diabetes Association’s (ADA’s) 85th Scientific Sessions.
An embargo means that information from any abstract or presentation is confidential and may not be announced, publicized, or distributed before the embargo date and time. This policy applies to all formats of release, including the Scientific Sessions online itinerary planner, meeting app, Abstracts on USB, abstracts published on the journal Diabetes® website, and any other distribution method.
The purpose of the embargo policy is to protect the scientific integrity of the abstract submissions presented at the ADA’s Scientific Sessions. All submissions are to be considered preliminary until the time of presentation or authorized for public release. Violation of the embargo policy by release of information contained in any abstract prior to its embargoed date and time will result in the individual, as well as the employer/affiliated company, institution, organization, etc., being removed from ADA’s 85th Scientific Sessions, with a two-year ban on returning.
Prior Publication
If the abstract is also submitted as a manuscript for publication, authors are responsible for coordinating a publication date and time that aligns with the Association’s embargo policy. If publication occurs online or in print before the specific embargo date and time set by the Association, the abstract must be withdrawn. Please notify the Association via email at abstracts@diabetes.org. Failure to notify the Association of publication will result in a moratorium on the submission of abstracts for all authors in question for two years. Note that the Association will not delay embargo times to align with a publication.
Specific Embargo Dates and Times:
*Oral Presentations:
Abstracts selected for oral presentation, are embargoed from the time of submission until the scheduled start of their presentation at the 85th Scientific Sessions. The ADA reserves the right to adjust the embargo as needed.
*Poster Presentations (including Late Breaking Posters):
Abstracts selected for poster presentation are embargoed from the time of submission until Friday, June 20, 2025 at 6:30 PM CT.
* Symposia:
This information is embargoed until the scheduled start of the specific symposium.
Published Only:
Abstracts selected for Published Only are embargoed from the time of submission until Friday, June 20, 2025 at 10:30 AM CT.
Regular and Late Breaking Abstract Availability
The embargoed text of most of the abstracts will be made available online on Friday, June 13, 2025.
Note: The abstract embargo still applies; however, abstracts are made available to attendees to assist in creating their itineraries for the meeting. *Not all abstracts will be available to view as some will follow the Press Program Abstract Availability timeline (see below).
ADA’s 85th Scientific Press Program Abstract Availability
Full text of abstracts selected for the ADA’s official 85th Scientific Sessions Press Program will be made available at the following times:
*Poster Presentations (including Late Breaking Posters): Full text of abstracts will be released on Friday, June 20th at 6:30 pm Central Time.
*Oral Presentations: Full text of abstracts will be released at the start time of the oral presentation at the 85th Scientific Sessions.
Exception to Embargo Policy―Publicly Traded Companies:
A pharmaceutical or device manufacturer that is publicly traded may be advised by its legal counsel that, in order to comply with requirements of the U.S. Securities Exchange Commission (SEC) or a corresponding regulatory body in the country where the company’s stock is traded, it must publicly disclose certain data from its submitted abstract prior to the Association’s authorized release of the abstract. Under such extenuating circumstances, and upon appropriate request, the American Diabetes Association may grant an exception to its embargo policy and allow the company to release limited top-line data from the abstract without jeopardizing its eligibility to be presented at the Association’s Scientific Sessions. To request such an exception, the following information needs to be sent via email to abstracts@diabetes.org and copy the corresponding author of the abstract.
- A letter signed by legal counsel to the American Diabetes Association (see sample letter) stating that disclosure of the information is necessary to comply with applicable securities laws.
- A draft press release (see sample press release) with data to be included, such as: general findings with no additional analysis, commentary, or investigator quotes, and timing of the release. The release must note that the abstract has been accepted for presentation at the American Diabetes Association’s Scientific Sessions, and that all abstracts are preliminary until time of presentation. The release must also clearly display the embargo date and time.
Information that goes beyond the four corners of the abstract (such as additional analysis, commentary, or updated information from those individuals and companies involved in the study) remains embargoed until the Association’s authorized release of the abstract. The company issuing the release assumes responsibility for ensuring embargoed releases are only distributed to parties including reporters or social media operators who agree to the Association’s embargo policy.
The Association will evaluate exception requests on a case-by-case basis and reserves the right to change the type of presentation (from oral presentation to poster presentation) or remove the abstract from the meeting program if it determines that the released information may substantially detract from the novelty of the presentation.
Questions regarding the correct embargo dates/times for the Association’s Scientific Sessions can be addressed to abstracts@diabetes.org and SciSessionsPress@diabetes.org.